These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7909396)

  • 21. Anxiolytic-like effect of way-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience.
    Canto-de-Souza A; Luiz Nunes-de-Souza R; Rodgers RJ
    Brain Res; 2002 Feb; 928(1-2):50-9. PubMed ID: 11844471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice.
    Bourin M; Hascoët M
    Behav Brain Res; 2010 Apr; 208(2):352-8. PubMed ID: 20006646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
    Kolik LG; Gudasheva TA; Seredenin SB
    Bull Exp Biol Med; 2012 Oct; 153(6):851-4. PubMed ID: 23113301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The neurochemical profile of the caudate nucleus in the anxiolytic action of benzodiazepine and nonbenzodiazepine tranquilizers on different models of anxiety].
    Talalaenko AN; Gordienko DV; Markova OP
    Eksp Klin Farmakol; 2000; 63(1):14-8. PubMed ID: 10763103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects.
    Ramos Ade T; Homem KS; Suchecki D; Tufik S; Troncone LR
    Behav Brain Res; 2014 May; 265():69-75. PubMed ID: 24569014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabotropic glutamate receptors as targets for novel anxiolytics.
    Ferraguti F
    Curr Opin Pharmacol; 2018 Feb; 38():37-42. PubMed ID: 29494817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
    Yamaguchi T; Tsujimatsu A; Kumamoto H; Izumi T; Ohmura Y; Yoshida T; Yoshioka M
    J Ethnopharmacol; 2012 Sep; 143(2):533-9. PubMed ID: 22819689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCK-antagonists in a rat exposed to acute stress: implication for anxiety associated with post-traumatic stress disorder.
    Cohen H; Kaplan Z; Kotler M
    Depress Anxiety; 1999; 10(1):8-17. PubMed ID: 10499184
    [No Abstract]   [Full Text] [Related]  

  • 30. Behavioral neurobiology of anxiety and its treatment. Preface.
    Stein MB; Steckler T
    Curr Top Behav Neurosci; 2010; 2():v-vii. PubMed ID: 21309102
    [No Abstract]   [Full Text] [Related]  

  • 31. A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.
    Koroleva SV; Ashmarin IP
    Neurosci Behav Physiol; 2006 Feb; 36(2):157-62. PubMed ID: 16380829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of selective anxiolytic compounds.
    Boulenger JP; Bisserbe JC
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():529A-530A. PubMed ID: 1354061
    [No Abstract]   [Full Text] [Related]  

  • 33. Cholecystokinin receptors in relation to brain dopaminergic pathways.
    Woodruff GN
    Neurochem Int; 1992 Mar; 20 Suppl():339S-343S. PubMed ID: 1365453
    [No Abstract]   [Full Text] [Related]  

  • 34. Anxiolytics.
    Sinclair LI; Nutt DJ
    Handb Clin Neurol; 2012; 106():669-79. PubMed ID: 22608651
    [No Abstract]   [Full Text] [Related]  

  • 35. The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?
    Pitsikas N
    Eur J Pharmacol; 2014 Jan; 723():181-4. PubMed ID: 24361306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzodiazepines, putative anxiolytics and animal models of anxiety.
    Green S
    Trends Neurosci; 1991 Mar; 14(3):101-4. PubMed ID: 1709533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.
    Duxon MS; Starr KR; Upton N
    Br J Pharmacol; 2000 Aug; 130(7):1713-9. PubMed ID: 10928979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet serotonin uptake in panic disorder: comparison with normal controls and the effect of treatment.
    Norman TR; Gregory MS; Judd FK; Burrows GD; McIntyre IM
    Aust N Z J Psychiatry; 1988 Dec; 22(4):390-5. PubMed ID: 2907288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link.
    Stahl SM
    J Clin Psychiatry; 1997; 58 Suppl 8():20-6. PubMed ID: 9236732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
    Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W
    Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.